Sign in

VVUS on NASDAQ

Vivus

Logo: vivus.com5

Pharmaceutical Company

Vivus (OTCID Basic: VVUSQ) is a small pharmaceutical company headquartered in Campbell, California that specializes in obesity, sleep, and sexual health. Vivus developed Avanafil, an erectile dysfunction drug that has completed Phase 3 clinical trials. The drug has been approved for use by the Food and Drug Administration, and is sold under the trademark name Stendra.3 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1991Founded1

Compare with another stock.

  • TickerVVUS on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersMountain View1
  • Websitewww.vivus.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business address900 E. Hamilton Avenue, Suite 550, Campbell, Ca 950086
  • Filer categoryNon-accelerated filer, Smaller reporting company6
  • LEI549300PC33SFMFILV6124
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 26245594

See how the biggest companies compare on our leaderboards

Vivus (OTCID Basic: VVUSQ) is a small pharmaceutical company headquartered in Campbell, California that specializes in obesity, sleep, and sexual health. Vivus developed Avanafil, an erectile dysfunction drug that has completed Phase 3 clinical trials. The drug has been approved for use by the Food and Drug Administration, and is sold under the trademark name Stendra. Stendra is the first and only oral erectile dysfunction treatment approved to be taken approximately 15 minutes before sexual activity.3

What it owns

What Vivus reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.0M7 Dec 31, 2019$2.9M7 Dec 31, 2018+1.4%
Accumulated depreciation$2.7M7 Dec 31, 2019$2.6M7 Dec 31, 2018+5.8%
Property and equipment, net$233.0K7 Dec 31, 2019$341.0K7 Dec 31, 2018−31.7%
Finance-lease assets$354.0K7 Dec 31, 2019$329.0K7 Jan 1, 2019+7.6%
Operating-lease assets (leased space)$781.0K7 Dec 31, 2019$1.2M7 Jan 1, 2019−35.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$32.6M7 Dec 31, 2019$30.4M7 Dec 31, 2018+7.4%
Marketable securities, current$07 Dec 31, 2019$80.8M7 Dec 31, 2018−100.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Accumulated amortization$25.4M7 Dec 31, 2019$10.9M7 Dec 31, 2018+133.8%
Finite-lived intangibles, net$119.5M7 Dec 31, 2019$134.1M8 Dec 31, 2018−10.9%

Inventory

ItemLatestA year beforeChange
Inventory, total$33.7M7 Dec 31, 2019$23.1M7 Dec 31, 2018+45.6%
Raw materials$26.3M7 Dec 31, 2019$17.8M7 Dec 31, 2018+47.7%
Work in process$2.9M7 Dec 31, 2019$1.7M7 Dec 31, 2018+69.2%
Finished goods$4.5M7 Dec 31, 2019$3.6M7 Dec 31, 2018+23.8%

Leadership

Who has led Vivus, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Leland F. Wilson2006–2013
  2. Anthony P. Zook2013
  3. Thomas Braxton King2018
  4. John P. Amos2018–2020

Chair

  1. Virgil A. Place2006–2007

President

  1. Leland F. Wilson2006–2009
  2. Peter Y. Tam2009–2013
  3. Kenneth Suh2018–2019

Chief financial officer

  1. Timothy E. Morris2006–2013
  2. Svai S. Sanford2013–2015
  3. Johann Noor Mohamed2015
  4. Mark K. Oki2015–2020

Chief operating officer

  1. Peter Y. Tam2009
1995200020052010201520202025
Board members and other officers (39)

Timeline

  1. May 2, 2018New chief executive John P. Amos becomes CEO10
  2. Jan 30, 2018New chief executive Thomas Braxton King becomes CEO9
  3. Jul 29, 2013New chief executive Anthony P. Zook becomes CEO11
  4. Jan 31, 2006New chief executive Leland F. Wilson becomes CEO12
  5. 1991Founded Founded1

Calendar

Drug trials and FDA: coming up

  1. Mar 31, 2027Phase 2 trial readout expected Phase 2 trial of VI-0609 and BiCNU in Lymphoma: primary completion expected Mar 31, 2027 (ClinicalTrials.gov NCT06915246).55

Drug trials and FDA: recently

  1. Sep 13, 2024FDA approved a new use FDA approved an efficacy supplement for Qsymia (phentermine hydrochloride), a new use or patient group (NDA 022580, supplement 25).56

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

SEC filer profile

How Vivus is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARVIVUS INC2
  • CIK0000881524
  • Employer ID (EIN)94-31361792
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address900 E. Hamilton Avenue, Suite 550, Campbell, CA 950082
  • Phone65093452002
  • Shares outstanding17,867,697 as of Apr 30, 202057
  • Public float$39.8M as of Jun 30, 20197
  • On EDGAR sinceMay 31, 19962
  • Filings1,671 in all: 4 (572), 8-K (505), SC 13G/A (82), 10-Q (72), SC 13G (41), 3 (38), DEFA14A (37), CT ORDER (36)2
    All 53 form types

    DFAN14A (31), UPLOAD (23), 10-K (22), DEF 14A (22), S-8 POS (21), S-8 (18), 4/A (17), 424B5 (14), 8-K/A (13), SC 13D/A (12), 10-K/A (11), CORRESP (10), EFFECT (6), S-3 (6), 5 (5), ARS (5), SC 13D (5), 10-Q/A (3), 3/A (3), POS AM (3), PRE 14A (3), S-3/A (3), 10-K405 (2), 8-A12B (2), 8-A12G/A (2), DEFC14A (2), DEFR14A (2), PREC14A (2), REGDEX (2), RW (2), S-1 (2), 10-C (1), 15-12B (1), 25-NSE (1), 424B1 (1), 424B3 (1), 8-A12B/A (1), 8-B12G (1), FWP (1), NT 10-Q (1), POSASR (1), PRER14A (1), PRRN14A (1), S-1/A (1), S-3ASR (1)

  • Latest filingsAnnual report (10-K) Mar 3, 2020
    Quarterly report (10-Q) May 6, 2020
    Proxy statement (DEF 14A) Apr 17, 2019
    Latest 8-K (8-K) Nov 16, 2020

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Company websiteVivus logo
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57